
The new drug application submission of parsaclisib (Incyte) was based on data from several phase 2 studies that evaluate the treatment.

The new drug application submission of parsaclisib (Incyte) was based on data from several phase 2 studies that evaluate the treatment.

SER-109, an investigational, oral, biologically-sourced microbiome therapeutic designed to reduce recurrence of C. difficile infection (CDI), demonstrated a 31.1% absolute reduction in the rate of CDI recurrence over 12 weeks compared to placebo

Michael Hogue joins Ed Cohen and John Beckner to dig deeper into vaccine hesitancy, boosters, and other topics in the immunization space.

Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses common themes or key points being raised in the field of psychedelic medicine at recent conferences.

Swim-Ear helps to soften, loosen, and remove earwax.

Voltaren treats osteoarthritis pain in the joints amenable to topical treatment, such as the knees and the hands.

Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses the factors associated with progression-free survival and overall survival in the treatment of Burkitt lymphoma.

Endometriosis most commonly involves the ovaries, fallopian tubes, and the tissue lining the pelvis.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses the therapeutic strategies or treatments for vascular calcification that have been found to be effective in patients with chronic kidney disease.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses the challenges of treating neuroendocrine tumors in large cancer centers.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses what the current clinical therapeutic strategies and novel treatments are for vascular calcification.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how large cancer centers are able to manage adverse events for individuals with neuroendocrine tumors.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses the cardiovascular effects of chronic kidney disease.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how large cancer centers are able to manage care for individuals with many different physicians.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses how medial vascular calcification impacts early vascular aging.

Mei Ka Fong, PharmD, BCOP, said oral oncolytics have traditionally always been a major part of the treatment for neuroendocrine tumors.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses how pharmacists are limited to traditional treatment of chronic kidney disease, while waiting for new treatment options.

Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses what early vascular aging is, and what its implications are when it occurs in patients with chronic kidney disease.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses promising new crystallization treatment of vascular calcification.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses the importance of pharmacists in helping treat individuals with neuroendocrine tumors.

Clinicians explored at-home monthly injections of somatostatin analogues during the early days of the COVID-19 pandemic in order to keep patients out of health care facilities as much as possible.

Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses the different treatment options that could help individuals with neuroendocrine tumors, emphasizing the importance of nutrition.

Experts address cases for and against the use of surgical resection in the treatment of patients with neuroendocrine tumors and liver metastases.

Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses what the different kinds or research shows about integrative medicine and the potential risk of this treatment.

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how large cancer centers provide patient-centered care.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses the effects of vascular calcifications if not successfully prevented.

Surufatinib targets both the VEGF receptor and the CSF1R receptor, which is a unique mechanism of action.

Rodney Pommier, MD, FACS, professor of surgery, Oregon Health & Science University, provides conclusions based on the prospective study findings investigating the treatment of carcinoid crisis without perioperative octreotide.

Kaushal Nanavati, MD, assistant dean of wellness and director of integrative medicine and survivorship at the Upstate Cancer Center discusses what integrative medicine is and how it can be used in conjunction with established cancer treatments.

Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses the role pharmacists play in helping individuals with vascular calcification and chronic kidney disease.